KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesAssez bien calibréProbabilité implicite actuelle
Above 8% 92%En tête parmi 9 options
Qualité du marché
62 / 100
Qualité moyenneVolume 24h
2,6 k €
Liquidité
2,3 k €
Liquidité moyenneÉcart
1.0 pt
Spread serréDonnées du marché
Mis à jour il y a 4 minutes
9 sept. 26, 02:00 UTC31 mars 27, 05:00 UTC
Tendances
0%
0%
0%
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
Medtronic cardiovascular organic growth in fiscal 2027
KalshiWill I believe the post "Cardiovascular disease is a solved problem" is broadly correct in August 2028?
Manifold MarketsWhen will Compass Pathways submit a NDA for COMP360 psilocybin?
KalshiWill 3 mg THC beverages be federally legal to sell?
KalshiWill there be >250k tech layoffs in 2027 according to Layoffs.fyi?
Manifold MarketsWill Aurelia Song abandon Nectome before 2041?
Manifold MarketsRègles
If Medtronic plc reports Above 8% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
Règlement via:Fiscal.ai
- Kalshi is not affiliated, associated, authorized, endorsed by, or in any way officially connected with the underlying company.
- All trademarks, logos, and brand names are the property of their respective owners.
- If Medtronic plc reports Above 9% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- If Medtronic plc reports Above 10% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- If Medtronic plc reports Above 10.5% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
Marchés ouverts
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Volume total
- 15,6 M €
- Volume 24h
- 20,4 k €
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Volume total
- 919 k €
- Volume 24h
- 4,2 k €
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k+0.1pt100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 résultats de plus
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000+3.0pt61%
+2 résultats de plus
- Volume total
- 866,7 k €
- Volume 24h
- 1,7 k €
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Volume total
- 611,8 k €
- Volume 24h
- 1,1 k €
KALSHIWhen will Beam Therapeutics submit a BLA for Risto-cel?
- before April 202793%
- before 202756%
- before December49%
+3 résultats de plus
- Volume total
- 19,1 k €
- Volume 24h
- 1 k €
- Which countries will report an Ebola disease case before October?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Heidi Overton confirmed as FDA Commissioner by which date?
- Will the FDA approve retatrutide?
- Ebola pandemic in 2026?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- Measles cases in U.S. by September 30?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- FDA approves Retatrutide this year?
Questions fréquentes
- Quelles sont les probabilités actuelles pour Medtronic cardiovascular growth in Q2 ?
- Kalshi cote Above 8% à 92% au 10 septembre 2026.
- Quand Medtronic cardiovascular growth in Q2 sera-t-il résolu ?
- Medtronic cardiovascular growth in Q2 doit être résolu le 31 mars 2027.
- Comment Medtronic cardiovascular growth in Q2 est-il réglé ?
- Kalshi règle ce marché comme suit : If Medtronic plc reports Above 8% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.